KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Cash from Financing Activities (2017 - 2025)

Guardant Health (GH) has disclosed Cash from Financing Activities for 9 consecutive years, with $732.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 25041.33% to $732.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $671.1 million through Dec 2025, up 67482.83% year-over-year, with the annual reading at $671.1 million for FY2025, 67482.83% up from the prior year.
  • Cash from Financing Activities hit $732.0 million in Q4 2025 for Guardant Health, up from $4.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $732.0 million in Q4 2025 to a low of -$172.1 million in Q2 2022.
  • Historically, Cash from Financing Activities has averaged $44.6 million across 5 years, with a median of $806000.0 in 2022.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 7016.67% in 2023 and later skyrocketed 25041.33% in 2025.
  • Year by year, Cash from Financing Activities stood at $3.8 million in 2021, then plummeted by 38.68% to $2.3 million in 2022, then soared by 3807.16% to $90.6 million in 2023, then crashed by 103.24% to -$2.9 million in 2024, then surged by 25041.33% to $732.0 million in 2025.
  • Business Quant data shows Cash from Financing Activities for GH at $732.0 million in Q4 2025, $4.3 million in Q3 2025, and $1.6 million in Q2 2025.